Please login to the form below

Not currently logged in
Email:
Password:

Par Pharmaceutical

This page shows the latest Par Pharmaceutical news and features for those working in and with pharma, biotech and healthcare.

Hikma pays $2.6bn for Boehringer’s US generics unit

Hikma pays $2.6bn for Boehringer’s US generics unit

There have been a number of generic deals this year, including Pfizer's $15bn deal for Hospira in February and Endo International's $8bn purchase of Par Pharmaceutical in May.

Latest news

  • Perrigo warming to Mylan - at the right price Perrigo warming to Mylan - at the right price

    Most recently, Endo has just agreed an $8.1bn deal to acquire Par Pharmaceutical and boost its generics business.

  • Endo buys Par for $8bn as M&A mania marches on Endo buys Par for $8bn as M&A mania marches on

    Endo is the latest to step up, offering just over $8bn for Par Pharmaceutical in order to boost its generics business. ... The acquisition comes after Endo tried and failed to merge with Salix Pharmaceutical earlier this year, eventually losing out to

  • Par buys Anchen in $410m deal

    Par buys Anchen in $410m deal. US-based Par Pharmaceutical is to purchase generic medicines manufacturer Anchen Pharmaceuticals. ... Par Pharmaceutical Companies is to acquire Anchen Pharmaceuticals, a privately owned speciality pharmaceutical company

  • Par to acquire Indian generics firm

    Par to acquire Indian generics firm. US-based Par Pharmaceutical has entered into a definitive agreement to acquire India's Edict Pharmaceuticals, a privately held developer and manufacturer of solid oral ... The US-based speciality pharma company Par

  • Pozen files to block generic migraine drug

    Pozen files to block generic migraine drug. Pozen has filed a motion to block Par Pharmaceutical from launching a generic version of the migraine drug Treximet, which is marketed in the ... Pozen has filed a motion to block Par Pharmaceutical from

More from news
Approximately 1 fully matching, plus 12 partially matching documents found.

Latest Intelligence

  • Deal Watch table for January 2014 Deal Watch table for January 2014

    510. JHP/ Par Pharmaceuticals. Company acquisition. Par acquires JHP, a leading specialty pharmaceutical company of branded and generic sterile injectables.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Par hires Antonio Pera as commercial head Par hires Antonio Pera as commercial head

    Par Pharmaceutical Companies has appointed Antonio Pera as chief commercial officer, leading the company's newly-integrated sales and marketing division following the acquisition of JHP Pharmaceuticals. ... Tony has enjoyed a distinguished career in the

  • Eisai appoints Lynn Kramer chief clinical officer Eisai appoints Lynn Kramer chief clinical officer

    Prior to joining Eisai, Dr Krammer had already spent more two decades in the pharmaceutical industry, serving at companies such as PAR Pharmaceutical, Ciba Geigy and Novartis.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Just::Health Communications

Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics